RespireRx Pharmaceuticals Inc (RSPI)

[money4retirement]

"One way around that problem might be to first run the entire cohort of patients through an opioid-only regimen to identify which patients experience significant RD and at what doses. Then on another day these same patients could be run through the same opioid dosing regimen but get CX-717 first."
--------------------------------------------------------------
hopefully those that experience significant rd will still be alive the following day.

==============================================================
==============================================================
"...it's a shame we don't have an IV formulation so we could run a true "rescue" type trial."
--------------------------------------------------------------
why is that. why can't they make an iv formulation for the trial?? what did the researchers in alberta use in their trials??? oral, injection, iv -- ????
==============================================================
what is the greater likely use, prevention or rescue of rd??

perhaps one of our posters that communicate with dr stoll via email could ask him WHY they will be using an oral formulation of cx717 instead of an iv formulation which would seem to be a superior delivery method, at least for the initial testing.